<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04168372</url>
  </required_header>
  <id_info>
    <org_study_id>M-3018</org_study_id>
    <nct_id>NCT04168372</nct_id>
  </id_info>
  <brief_title>Fructose: Substrate, Stimulus, or Both?</brief_title>
  <official_title>Fructose: Substrate, Stimulus, or Both?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Touro University, California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Touro University, California</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This objective of this study is to use sensitive methodology under controlled conditions to
      investigate the mechanisms by which fructose consumption contributes to excess fatty acid
      synthesis and elevations in blood glucose levels following consumption of meals containing
      fructose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic fractional de novo lipogenesis in triglyceride rich lipoprotein (TRL)</measure>
    <time_frame>6 hours</time_frame>
    <description>Measured by the detection of 13C carbons in TRL-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of appearance of UDP-glucose</measure>
    <time_frame>6 hours</time_frame>
    <description>An estimate of hepatic glycogen flux measured by administration of D1 galactose and acetaminophen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of appearance of blood glucose from gluconeogenesis</measure>
    <time_frame>6 hours</time_frame>
    <description>Measured by the dilution method of labeled glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum triglyceride concentration</measure>
    <time_frame>6 hours</time_frame>
    <description>Fasting and postprandial serum triglyceride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum glucose concentration</measure>
    <time_frame>6 hours</time_frame>
    <description>Fasting and postprandial serum triglyceride levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lactate concentration</measure>
    <time_frame>6 hours</time_frame>
    <description>Fasting and postprandial serum lactate levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>6 hours</time_frame>
    <description>Fasting and postprandial insulin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum free fatty acid concentration</measure>
    <time_frame>6 hours</time_frame>
    <description>Fasting and postprandial fatty acid levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enteral (chylomicron) fractional de novo lipogenesis (DNL)</measure>
    <time_frame>6 hours</time_frame>
    <description>Measured by the detection of 13C carbons in chylomicron-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic (VLDL) fractional de novo lipogenesis (DNL)</measure>
    <time_frame>6 hours</time_frame>
    <description>Measured by the detection of 13C carbons in VLDL-palmitate from administered 13C labeled pyruvate or 13C labeled fructose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrasplanchnic fructose</measure>
    <time_frame>6 hours</time_frame>
    <description>Calculated using total plasma fructose, plasma 2-13C fructose enrichment, and endogenous fructose production</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body fructose oxidation</measure>
    <time_frame>6 hours</time_frame>
    <description>Measured by 13C atom % excess in exhaled breath, and VCO2 by indirect calorimetry</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Pre Diabetes</condition>
  <arm_group>
    <arm_group_label>High fructose meal, with fructose label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-13C fructose incorporated into a meal with high fructose content</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High fructose meal, with pyruvate label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-13C pyruvate incorporated into a meal with high fructose content</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low fructose meal, with fructose label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-13C fructose incorporated into a meal with low fructose content</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low fructose meal, with pyruvate label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2-13C pyruvate incorporated into a meal with low fructose content</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High fructose, fructose labeled meal</intervention_name>
    <description>Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose</description>
    <arm_group_label>High fructose meal, with fructose label</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>High fructose, pyruvate labeled meal</intervention_name>
    <description>Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate</description>
    <arm_group_label>High fructose meal, with pyruvate label</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low fructose, fructose labeled meal</intervention_name>
    <description>Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose</description>
    <arm_group_label>Low fructose meal, with fructose label</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low fructose, pyruvate labeled meal</intervention_name>
    <description>Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate</description>
    <arm_group_label>Low fructose meal, with pyruvate label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index 22 to 30 kg/m2

          -  Prediabetic (HbA1c between 5.8-6.5%) or hyperinsulinemic (fasting insulin ≥12 µIU/mL)
             but non-diabetic (fasting glucose &lt;126mg/dL and HbA1c &lt; 6.5%) ; or normal control
             (fasting insulin &lt;10 µIU/mL, fasting glucose &lt;100 mg/dL, and HbA1c &lt; 5.7%)

        Exclusion Criteria:

          -  Pregnancy or lactation within the past six months

          -  Type 1 or 2 diabetes mellitus

          -  History of liver disease or AST and ALT above the upper limit of normal (ULN)

          -  Fasting triglyceride or total cholesterol levels above ULN

          -  Hemoglobin or hematocrit below the lower limit of normal for sex

          -  Report of hepatitis or HIV infection;

          -  History of cancer, use of any anti-diabetic medications or hypolipidemic agents in the
             past six months;

          -  History of surgical procedure for obesity

          -  Self-reported change in body weight &gt;5% in the past six months

          -  History of other conditions known to affect insulin sensitivity and lipid metabolism

          -  Known intolerance to acetaminophen or components of the liquid test meals
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Schwarz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Touro University, California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Chiu, PhD</last_name>
    <phone>707-638-5404</phone>
    <email>sally.chiu@tu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Touro University California</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94592</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Schwarz, PhD</last_name>
      <phone>707-638-5456</phone>
      <email>jean-marc.schwarz@tu.edu</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Schwarz, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>March 22, 2020</last_update_submitted>
  <last_update_submitted_qc>March 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fructose</keyword>
  <keyword>Glucose</keyword>
  <keyword>Lipogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

